MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors - Quiz - MDSpire

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • By

  • May 7, 2026

  • 4 min

Share

Original Source(s)

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

  • by

  • May 7, 2026

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease